<DOC>
	<DOC>NCT02563054</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of oral capecitabine (Xeloda) versus 5-fluorouracil (5-FU), in combination with intravenous (IV) cisplatin, in participants with advanced and/or metastatic gastric cancer. The anticipated time on study treatment is at least 6 weeks and continued up to disease progression, and the target sample size is 300 individuals.</brief_summary>
	<brief_title>A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Adults 18 to 75 years of age Advanced and/or metastatic gastric cancer with at least 1 measurable lesion Uncontrolled infection Evidence of central nervous system (CNS) metastases History of other malignancy within the last 5 years, except cured basal cell cancer of the skin or cured insitu cancer of the uterine cervix Radiation therapy or major surgery within 4 weeks of study drug Previous chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>